Related Experiment Videos
[Cushing's syndrome is still a potentially fatal disease]
1Endokrinologický ústav v L'ubochni.
Insights
Patients with Cushing's syndrome face significantly higher cardiovascular mortality, even after treatment resolves hypercortisolism. Early screening and ongoing cardiovascular monitoring are crucial for managing this persistent risk.
Area of Science:
- Endocrinology
- Cardiology
- Internal Medicine
Abstract:
The paper summarizes the studies documenting the outlasting of increased cardiovascular mortality in patients with Cushing's syndrome even after the hypercortisolism resolution. Despite the hypercortisolism resolution the mortality during the subsequent period of life is up to four-fold higher than in the comparable population as a whole. The pathogenesis of this cardiovascular risk is based on arterial hypertension, steroid cardiomyopathy and hyperlipidaemia with subsequent atherosclerosis. The post mortem material bears a parallel of the extent of atheromatous changes and duration of hypercorticolism. The prevention has to its disposition two mutually complementing means. The first is represented by clinical screening of hypercorticolism which enables an early recognition and therapy of the Cushing's syndrome. The successive measure resides in increased attention to the cardiovascular system even after hypercorticolism resolution. (Tab. 1, Fig. 1, Ref. 25.).